How long can you take tirzepatide, and what does the evidence say?

What 72 weeks of trial data actually showed about duration

The SURMOUNT-1 trial (the cornerstone evidence behind tirzepatide's UK weight-management licence) followed 2,539 adults across 72 weeks. Average body-weight reduction at the highest dose reached around 20–21%, and critically, weight loss continued to accumulate over the full length of the study rather than plateauing early. There was no signal in the data to suggest a point at which treatment should routinely stop.

That 72-week timeframe was chosen for regulatory purposes, not as a practical ceiling. It gave the MHRA and NICE enough data to assess safety and efficacy, but the licensed indication for weight management carries no expiry date written into it. NICE's appraisal of tirzepatide (NICE TA1026) focuses on whether treatment is still working, not on how many months have passed.

The trial findings also shed light on what happens when treatment stops. A separate extension analysis showed that participants who discontinued tirzepatide regained a substantial proportion of lost weight within a year. This finding is clinically important: it reframes how long you take tirzepatide from "a course" into "an ongoing treatment decision", which is how most prescribers now think about it.

How the 5% rule and NICE guidance shape real prescribing decisions

There is a common assumption that GLP-1 medicines are intended as a short, intensive course, a few months of injections and then done. That is not how the licensed guidance reads.

NICE TA1026 sets one specific duration-related checkpoint: if a patient has not achieved at least 5% weight loss after six months at the highest tolerated dose, the prescriber should reconsider whether continuing is appropriate. That threshold applies in both directions, if it is met, there is no guidance saying treatment should stop.

Beyond that review point, continuation depends on clinical judgement. Your prescriber will look at ongoing weight loss, any weight maintenance you are achieving, how well you are tolerating the medicine, and whether your weight-related health conditions are improving. The NHS patient information for tirzepatide is clear that treatment should continue as long as your prescriber considers it appropriate and the benefit-risk balance holds.

For people managing type 2 diabetes alongside weight, the same principle applies: tirzepatide is not a short-term fix in that indication either. Treatment duration is an ongoing clinical conversation, not a prescription that automatically runs out.

What stopping tirzepatide tends to mean in practice

One of the questions our prescribers hear regularly is whether you eventually reach a point where treatment is no longer needed. It is worth addressing honestly. Tirzepatide works while you are taking it; the biological drivers of weight (appetite-regulating hormones, metabolic set point, how the body defends its stored fat) do not permanently reset after a course of treatment ends.

Studies in longer-term extension periods consistently show weight regain when tirzepatide is discontinued. This does not mean treatment is intended to last forever for everyone, but it does mean decisions to stop should be made carefully with your prescriber, with a plan in place for what follows. Gradual dose reduction, ongoing lifestyle support, or transitioning to another approach may all be part of that discussion.

If you are thinking about how duration fits into the broader cost picture, our guide to Mounjaro pricing in the UK covers how treatment is typically structured and what to expect at each stage. For a fuller picture of how long you can stay on tirzepatide and the considerations involved in longer-term use, that page goes into more clinical detail.

How quickly the medicine begins to have an effect is a separate but related question. If you want to understand the early weeks of treatment, our page on how long tirzepatide takes to work walks through what to realistically expect dose by dose.

Duration, safety monitoring and what private prescribing looks like at nume

Prescribing tirzepatide for the long term requires active clinical oversight, not a standing order. At every point where a repeat is issued, there should be a review of weight progress, tolerance, any new health information, and whether the dose remains appropriate. For a full picture of what responsible clinical oversight looks like across the treatment journey, our page on how long you should take tirzepatide covers the clinical framework in more depth.

At nume, no repeat is issued without a prescriber re-reviewing your case. That is not a policy we added for reassurance, it is what clinically safe prescribing of a Prescription-Only Medicine requires. Our prescribers are GPhC-registered Independent Prescribers; a named clinician reads your information every time, not a system that approves automatically.

If you have been on tirzepatide through another service and want to continue, transfer patients are reviewed carefully, including a check of current dose evidence. The duration question (how long you have been taking it and how long you should continue) is central to that review. You can explore the full treatment pathway on our Mounjaro overview page, or read about how long weight loss typically takes on tirzepatide if that is the aspect you are weighing up.

When you are ready to talk to a prescriber about your own situation, you can check your eligibility and start a free consultation with our clinical team, same-day review, no waiting list, and no obligation.